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Background
The familial Mediterranean fever 50 score (FMF50) was
recently devised to define response to treatment and as
an outcome measure for clinical trials of FMF.
Objectives
To examine the performance of the FMF50 score in a
previously published trial of rilonacept [1] for patients
whose FMF was resistant or intolerant to colchicine.
Methods
We reanalyzed the data from the controlled trial of rilo-
nacept vs. placebo in 14 patients with colchicine-resistant
or intolerant FMF using the FMF50 score as the primary
outcome. The FMF50 score required improvement by
≥50% in five of six criteria (attack frequency, attack dura-
tion, global patient assessment, global physician assess-
ment, frequency of attacks with arthritis, and levels of
acute-phase reactants) without worsening of the sixth
criterion.
Results
In the original trial rilonacept was considered effective
according to the primary outcome measure (differences
in the attack frequency) with eight analyzable patients
considered responders and four as non-responders.
According to the FMF50 score, only two participants
would have been considered responders to rilonacept,
and one to placebo. Only two participants had ≥50% dif-
ferences between rilonacept and placebo in five criteria.
The major explanation for non-response to treatment
was that with rilonacept the duration of attack
decreased by ≥50% in only 2 participants and 5 partici-
pants had no attacks of arthritis either during screening
(before randomization) or during treatment with
rilonacept.
Conclusions
The proposed FMF50 score did not differentiate well
between responders and non-responders compared to
the a priori defined primary outcome measure in this
successful controlled study and should be revisited prior
to adoption as a primary outcome measure in multina-
tional FMF trials.
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